



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

## Hukyndra

### Procedural steps taken and scientific information after the authorisation\*

\*Due to the Agency's update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to **EPAR - Procedural steps taken and scientific information after authorisation (archive)**.

Application number	Scope	Opinion/ Notification <sup>1</sup> issued on	Commission Decision Issued <sup>2</sup> / amended on	Product Information affected <sup>3</sup>	Summary
Variation type II /	B.II.d.1 Change in the specification	24/07/2025		Annex II and	The Annex II has been updated as follows: The

<sup>1</sup> Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

<sup>2</sup> A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

<sup>3</sup> SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



EMA/VR/0000271897	parameters and/or limits of the finished product - B.II.d.1.e Change outside the approved specifications limits range - Accepted			PL	postal code of the manufacturer of the biological active substance(s) and of the manufacturer responsible for batch release has been amended from: Alvotech Hf Sæmundargata 15-19 Reykjavik, 101 Iceland To: Alvotech Hf Sæmundargata 15-19 Reykjavik, 102 Iceland The PL has been updated accordingly.
Variation type IB / EMA/VR/0000262181	<p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted</p>	22/05/2025	N/A		
Variation type II / EMA/VR/0000246665	<p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.a.3 Change in batch size (including batch size ranges) of active substance or intermediate used in the manufacturing process of the active substance - B.I.a.3.c The change requires assessment of the comparability of a biological/immunological</p>	08/05/2025	N/A		

	active substance - Accepted				
Variation type II / EMA/VR/0000246981	<p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted</p> <p>B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.d Substantial change to or replacement of a biological/ immunological/ immunochemical test method or a method using a biological reagent for a biological active substance - Accepted</p>	10/04/2025	N/A		